-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Upgrades Replimune Group to Outperform, Raises Price Target to $17

Benzinga·08/04/2026 09:22:40
Listen to the news
Leerink Partners analyst Jonathan Chang upgrades Replimune Group (NASDAQ:REPL) from Market Perform to Outperform and raises the price target from $11 to $17.